University of Sussex
Browse
cells-07-00176-v2.pdf (2.09 MB)

Inhibitory-?b kinase (IKK) a and nuclear factor-?B (NF?B)-inducing kinase (NIK) as anti-cancer drug targets

Download (2.09 MB)
journal contribution
posted on 2023-06-10, 04:55 authored by Andrew Paul, Joanne Edwards, Christopher PepperChristopher Pepper, Simon Mackay
The cellular kinases inhibitory-?B kinase (IKK) a and Nuclear Factor-?B (NF-?B)-inducing kinase (NIK) are well recognised as key central regulators and drivers of the non-canonical NF-?B cascade and as such dictate the initiation and development of defined transcriptional responses associated with the liberation of p52-RelB and p52-p52 NF-?B dimer complexes. Whilst these kinases and downstream NF-?B complexes transduce pro-inflammatory and growth stimulating signals that contribute to major cellular processes, they also play a key role in the pathogenesis of a number of inflammatory-based conditions and diverse cancer types, which for the latter may be a result of background mutational status. IKKa and NIK, therefore, represent attractive targets for pharmacological intervention. Here, specifically in the cancer setting, we reflect on the potential pathophysiological role(s) of each of these kinases, their associated downstream signalling outcomes and the stimulatory and mutational mechanisms leading to their increased activation. We also consider the downstream coordination of transcriptional events and phenotypic outcomes illustrative of key cancer ‘Hallmarks’ that are now increasingly perceived to be due to the coordinated recruitment of both NF-?B-dependent as well as NF-?B–independent signalling. Furthermore, as these kinases regulate the transition from hormone-dependent to hormone-independent growth in defined tumour subsets, potential tumour reactivation and major cytokine and chemokine species that may have significant bearing upon tumour-stromal communication and tumour microenvironment it reiterates their potential to be drug targets. Therefore, with the emergence of small molecule kinase inhibitors targeting each of these kinases, we consider medicinal chemistry efforts to date and those evolving that may contribute to the development of viable pharmacological intervention strategies to target a variety of tumour types.

History

Publication status

  • Published

File Version

  • Published version

Journal

Cells

ISSN

2073-4409

Publisher

MDPI AG

Issue

10

Volume

7

Page range

E176 1-30

Event location

Switzerland

Department affiliated with

  • Clinical and Experimental Medicine Publications

Full text available

  • Yes

Peer reviewed?

  • Yes

Legacy Posted Date

2022-09-30

First Open Access (FOA) Date

2022-09-30

First Compliant Deposit (FCD) Date

2022-09-30

Usage metrics

    University of Sussex (Publications)

    Categories

    No categories selected

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC